EGFR and hepatocellular carcinoma: The rationale for targeting the EGFR pathway comes from the following observations: there is a high frequency of EGFR overexpression in HCC [26-29], and this overexpression has been associated with late-stage disease, increased cell proliferation and degree of tumor differentiation [28-30].